6-Chlor-Δ⁶-Dehydro-17α-acetoxy-progesteron | 302-22-7

• 物质功能分类: 原料药 - 激素及调节内分泌功能类药 - 避孕药
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 6-Chlor-Δ⁶-Dehydro-17α-acetoxy-progesteron
• 英文别名: 6-Chlor-17α-acetoxy-Δ⁶-dehydro-progesteron；6-Chlor-4,6-pregnadion-17α-ol-3,20-dion-17-acetat；17α-Acetoxy-6-chlor-pregna-4,6-dien-3,20-dion；6-Chlor-4,6-pregnadien-17α-ol-3,20-dionacetat；17α-Acetoxy-6-chlorpregna-4,6-dien-3,20-dion；6-Chlor-6-dehydro-17α-acetoxy-progesteron；[(10R,13S,17R)-17-acetyl-6-chloro-10,13-dimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
• CAS: 302-22-7；4203-02-5
• 化学式: C₂₃H₂₉ClO₄
• 分子量: 404.934
• InChiKey: QMBJSIBWORFWQT-GDMUWPLKSA-N

物化性质

• 熔点：
  212°C
• 比旋光度：
  D +6° (c = 1 in CHCl3)
• 沸点：
  512.5±50.0 °C(Predicted)
• 密度：
  1.1345 (estimate)
• 溶解度：
  可溶于氯仿（少许）、乙酸乙酯（少许）、甲醇（少许）
• 最大波长(λmax)：
  285nm(EtOH)(lit.)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  60.4
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险品标志：
  T
• 安全说明：
  S22,S36/37/39,S45,S53
• 危险类别码：
  R60,R40,R48,R61
• WGK Germany：
  3
• 海关编码：
  29372390
• 危险品运输编号：
  NONH for all modes of transport

制备方法与用途

生物活性

Chlormadinone acetate (Gestafortin) 是一种甾族的黄体酮，具有抗雄激素和抗促性腺激素的作用。其半衰期约为34-38小时。

靶点

Target	Value
Androgen

用途

强效孕激素。

类别

有毒物质

毒性分级

低毒

急性毒性

• 口服 - 大鼠 LD50: >10,000毫克/公斤
• 口服 - 小鼠 LD50: >15,000毫克/公斤

可燃性危险特性

热分解排出有毒氯化物烟雾

储运特性

库房低温通风干燥

灭火剂

水、干粉、二氧化碳、泡沫

文献信息

• INTERSTITIAL PROSTATISM MODEL ANIMAL
  申请人：TAIHO PHARMACEUTICAL CO., LTD.

  公开号：EP1393623A1

  公开（公告）日：2004-03-03

  The present invention provides an animal model for prostatic stromal hyperplasia, and a method for screening for a substance effective for preventing/treating human benign prostatic hyperplasia using the animal model. The animal model for prostatic stromal hyperplasia is produced by implanting the fetal urogenital sinus of a non-human animal under the skin or beneath the prostatic capsule of a non-human animal belonging to the species of the same as or different from the said animal. A substance effective for preventing/treating human benign prostatic hyperplasia can be screened by administering a test substance to the animal model and measuring the preventive or therapeutic effect of the test substance upon the implanted tissue (fetal urogenital sinus or tissue derived therefrom).

  本发明提供了一种前列腺基质增生的动物模型，以及一种利用该动物模型筛选有效预防/治疗人类良性前列腺增生的物质的方法。前列腺基质增生的动物模型是通过将非人类动物的胎儿泌尿生殖窦植入与所述动物同种或不同种的非人类动物的皮下或前列腺囊下而制成的。通过对动物模型施用试验物质，并测量试验物质对植入组织（胎儿泌尿生殖窦或由其衍生的组织）的预防或治疗效果，可以筛选出预防/治疗人类良性前列腺增生症的有效物质。
• Interstitial prostatism model animal
  申请人：——

  公开号：US20040139486A1

  公开（公告）日：2004-07-15

  The present invention provides an animal model for prostatic stromal hyperplasia, and a method for screening for a substance effective for preventing/treating human benign prostatic hyperplasia using the animal model. The animal model for prostatic stromal hyperplasia is produced by implanting the fetal urogenital sinus of a non-human animal under the skin or beneath the prostatic capsule of a non-human animal belonging to the species of the same as or different from the said animal. A substance effective for preventing/treating human benign prostatic hyperplasia can be screened by administering a test substance to the animal model and measuring the preventive or therapeutic effect of the test substance upon the implanted tissue (fetal urogenital sinus or tissue derived therefrom).

  本发明提供了一种前列腺基质增生的动物模型，以及一种利用该动物模型筛选有效预防/治疗人类良性前列腺增生的物质的方法。前列腺基质增生的动物模型是通过将非人类动物的胎儿泌尿生殖窦植入与所述动物同种或不同种的非人类动物的皮下或前列腺囊下而制成的。通过对动物模型施用试验物质，并测量试验物质对植入组织（胎儿泌尿生殖窦或由其衍生的组织）的预防或治疗效果，可以筛选出预防/治疗人类良性前列腺增生症的有效物质。
• ANIMAL MODEL FOR PROSTATIC STROMAL HYPERPLASIA
  申请人：Oda Nobuyuki

  公开号：US20080255253A1

  公开（公告）日：2008-10-16

  The present invention provides an animal model for prostatic stromal hyperplasia, and a method for screening for a substance effective for preventing/treating human benign prostatic hyperplasia using the animal model. The animal model for prostatic stromal hyperplasia is produced by implanting the fetal urogenital sinus of a non-human animal under the skin or beneath the prostatic capsule of a non-human animal belonging to the species of the same as or different from the said animal. A substance effective for preventing/treating human benign prostatic hyperplasia can be screened by administering a test substance to the animal model and measuring the preventive or therapeutic effect of the test substance upon the implanted tissue (fetal urogenital sinus or tissue derived therefrom).
• COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING
  申请人：Bulawa Christine

  公开号：US20100305068A1

  公开（公告）日：2010-12-02

  Disclosed are compositions and methods for modulating protein trafficking and treating or preventing disorders characterized by impaired protein trafficking. Also disclosed are methods for producing a protein and identifying compounds that rescue protein trafficking defects.
• US7417175B2
  申请人：——

  公开号：US7417175B2

  公开（公告）日：2008-08-26